Barclays starts ABT coverage with Overweight and $120 target
Oct 7, 2026, 12:34 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Initiations with new price targets often prompt short-term price re-rating, especially when stock trades near a prior level and a well-known bank publishes a new PT. Historically, such coverage can generate momentum, but actual price moves depend on broader market sentiment and fundamentals aligning with the target. ABT has seen prior reactions to ratings news that were not guaranteed to persist, so the move may be intermittent.
AI summary
What happened, with direct paths to the underlying reporting
Barclays initiated Abbott Laboratories (ABT) with an Overweight rating and a $120 target, signaling confidence in continued growth. ABT trades around $98.16, implying roughly 22% upside to the target. This move comes amid a broader wave of analyst initiations, potentially bolstering near-term upside for ABT shares.
Barclays initiates ABT with Overweight and $120 target.
ABT closed at $98.16 on Tuesday.
Other initiations include HONA, MTB, SAIL, AMBQ.
Analysts signal renewed coverage across multiple names.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Abbott cut its 2026 sales growth forecast because of medical device weakness, highlighting vulnerabilities in the devices segment. The move raises near-term revenue risk for ABT a…
Abbott reports Q3 earnings on Oct 21 before the open, with consensus $1.41 per share on $12.99 billion revenue. The Oct 5 FDA approval for CardioMEMS HF System updates, including…
Rothschild & Co boosted Abbott Laboratories' price target from 119 to 127 and upgraded the stock to Buy, signaling renewed confidence in ABT's fundamentals. The move follows no st…
Abbott Laboratories agreed to pay more than $384 million to settle DOJ allegations tied to contaminated infant formula. The settlement resolves the lawsuit but signals ongoing reg…
